Page 13 - எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி படை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunovia reiterates its road to reimbursement for the IMMray™ PanCan-d test

Share this article LUND, Sweden, April 22, 2021 /PRNewswire/ Immunovia is launching its IMMray™ PanCan-d test in the US as a Laboratory Developed Test (LDT) in Q2 2021. The company will explore a positive Medicare coverage determination for the IMMray™ PanCan-d test through the Local Coverage Determination (LCD) process. The IMMray™ PanCan-d test will be performed at Immunovia Dx Laboratories in Marlborough, Massachusetts, and will be available to all patients in the US. In accordance with Medicare regulations, all Medicare billing will be conducted by Immunovia Dx Laboratories through the Medicare Administrative Contractor (MAC) that administers benefits in Massachusetts (National Government Services or NGS). Therefore, obtaining coverage from NGS would be sufficient for coverage of all Medicare-participating patients nationwide.

United statesDavid parkerPatrik dahlenMassachusetts national government servicesDepartment of immuntechnology at lund universityInternational cancer of the pancreas screeningUs preventive services task forceImmunovia dx laboratory in marlboroughLaboratory developed testHealth cancer centerLocal coverage determinationImmunovia dx laboratoriesMedicare administrative contractorNational government servicesInternational cancerPancreas screening

Immunovia presents update on US market size for IMMray™ PanCan-d in the familial/hereditary risk group

Share this article LUND, Sweden, April 21, 2021 /PRNewswire/ Immunovia today announced an updated assessment of the total market size for familial/hereditary pancreatic cancer risk group in the US. New estimations show that 315,000 – 350,000 individuals have a familial/hereditary risk for pancreatic cancer and would qualify to be enrolled in pancreatic cancer surveillance programs. Immunovia s bloodtest IMMray™ PanCan-d for early detection of pancreatic cancer is to be used for surveillance testing of high risk individuals. The recent blided validation study showed that IMMray™ PanCan-d and the tumor marker CA 19-9 detect stage I & II pancreatic cancer with 85% sensitivity and 98% specificity in familial/hereditary pancreatic cancer risk group.

United statesPrnewswire immunoviaPatrik dahlenAmerican society of clinical oncologyDepartment of immuntechnology at lund universityInternational cancer of the pancreas screeningUs preventive services task forceImmunovia dx laboratory in marlboroughHealth cancer centerNational comprehensive cancer networkServices task forceAmerican societyClinical oncologyInternational cancerPancreas screeningDegree relative

Immunovia presents update on US market size for IMMray PanCan-d in the familial/hereditary risk group

(1) LUND, Sweden, April 21, 2021 /PRNewswire/ Immunovia today announced an updated assessment of the total market size for familial/hereditary pancreatic cancer risk group in the US. New estimations show that 315,000 - 350,000 individuals have a familial/hereditary risk for pancreatic cancer and would qualify to be enrolled in pancreatic cancer surveillance programs. Immunovia s bloodtest IMMray PanCan-d for early detection of pancreatic cancer is to be used for surveillance testing of high risk individuals. The recent blided validation study showed that IMMray PanCan-d and the tumor marker CA 19-9 detect stage I & II pancreatic cancer with 85% sensitivity and 98% specificity in familial/hereditary pancreatic cancer risk group.

United statesPrnewswire immunoviaImmray pancan dPatrik dahlenAmerican society of clinical oncologyDepartment of immuntechnology at lund universityUs preventive services task forceInternational cancer of the pancreas screeningImmunovia dx laboratory in marlboroughHealth cancer centerNational comprehensive cancer networkServices task forceAmerican societyClinical oncologyInternational cancerPancreas screening

ACA Litigation Round-Up, Part 2: Which 2019 Payment Rule Changes Were Legal? Plus, More From Judge O Connor On The ACA

ACA Litigation Round-Up, Part 2: Which 2019 Payment Rule Changes Were Legal? Plus, More From Judge O Connor On The ACA
healthaffairs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthaffairs.org Daily Mail and Mail on Sunday newspapers.

United statesReed oconnorSteven hotzeMatthewj kacsmarykDeborahk chasanowJohn kelleyAmerican academy of actuariesDepartment of justiceHealth insurance taxHuman servicesHealth resourcesDistrict courtCircuit courtAdvisory committee on immunization practicesSupreme courtPublic health service

USPSTF Still Sour on Afib Screening, Even With Apple Watch

USPSTF Still Sour on Afib Screening, Even With Apple Watch
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.

United statesMayo clinic in rochesterChykea doubeniWhile the american academy of family physiciansUs preventive services task forceAmerican heart association strokeUs preventive services taskServices task forceApple watchMayo clinicMedpage todayAmerican academyFamily physiciansAmerican heartAmerican stroke associationAtrial fibrillation